V-ATPase C2, or the C subunit of vacuolar-type H+-ATPase, plays a critical role in the acidification of intracellular compartments, such as endosomes, lysosomes, and the Golgi apparatus. This enzyme is part of the proton pump complex that transfers protons across biological membranes, which is essential for various cellular processes including protein sorting, zymogen activation, and the degradation of macromolecules. The acidification process driven by V-ATPase C2 is also crucial for maintaining an acidic environment in osteoclasts, which is necessary for bone resorption. Thus, V-ATPase C2 is a key component in both normal cellular functions and specialized functions in certain cell types. The activity of V-ATPase C2 ensures that cellular pH is properly regulated, which affects many biochemical pathways and cellular functions that depend on specific pH conditions.
The inhibition of V-ATPase C2 can lead to significant changes in cellular physiology by disrupting the acid-base balance within cellular organelles, impacting processes like receptor-mediated endocytosis, protein degradation, and ion storage. Mechanisms of inhibition typically involve targeting the functionality of the V-ATPase complex, either by directly interfering with the assembly or stability of the complex, or by affecting its proton pumping capability. Small molecule inhibitors, for instance, can bind to the V-ATPase C2 subunit or associated components, blocking the proton channel or altering the conformation of the enzyme complex so that it becomes less efficient or entirely inactive. Genetic approaches such as RNA interference can also be used to reduce the expression of V-ATPase C2, thereby decreasing the overall activity of the proton pump. These inhibitory strategies affect the enzyme's ability to maintain pH homeostasis within organelles, potentially leading to alterations in cellular trafficking, signaling, and metabolism. The inhibition of V-ATPase C2, therefore, offers a window into understanding the essential roles of cellular pH in health and disease, providing insights into a fundamental aspect of cell biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Selective V-ATPase inhibitor that directly interacts with the V0 subunit, disrupting proton translocation and subsequently impeding V-ATPase C2 functionality. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Binds the V0 c-subunit of V-ATPase, inhibiting proton pumping and thus causing functional disruption of V-ATPase C2. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Proton pump inhibitor that reduces H+ ion concentration, indirectly attenuating V-ATPase C2 activity by diminishing substrate availability. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
Inhibits cyclooxygenase pathways, decreasing the need for proton pumping and thus reducing V-ATPase C2 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that alters intracellular signaling, leading to reduced translation and synthesis of V-ATPase C2. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
FGFR inhibitor that downregulates the MAPK pathway, causing a subsequent decrease in V-ATPase C2 expression. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $112.00 $449.00 $673.00 $1224.00 | 2 | |
MLCK inhibitor that reduces calcium-mediated intracellular signaling, indirectly affecting V-ATPase C2 activity. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
CaMKII inhibitor that modulates calcium signaling, indirectly impacting the need for V-ATPase C2 in vesicle acidification. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
CDK inhibitor that interferes with cell cycle progression, consequently decreasing the need for V-ATPase C2 function. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
PKA inhibitor that reduces cAMP levels, thereby lowering V-ATPase C2 activation via cAMP-dependent pathways. | ||||||